RE:NewsComment on LinkedIn from Dr. Sud Agarwal, CEO and cofounder of Cannvalate in Australia, regarding Valens new license approvals from the Australian government:
"Congrats to The Valens Company on another key milestone being crossed.
We are forecasting significant expansion in 2021 with both organic growth of the prescription cannabis market but also opening up of the schedule 3 OTC CBD market.
Valens are our manufacturing partner of choice for high quality, pharmaceutical grade cannabinoids currently being prescribed by physicians in our clinics. There is no substitute for quality."